Teri Foy, MD, PhD is an immunologist with more than 25 years of biotechnology and pharmaceutical industry experience developing novel therapeutics in the areas of oncology and inflammation. At Bristol Myers Squibb, Dr Foy leads the Immuno-Oncology and Cell Therapy Thematic Research Center. With a mission to drive leadership in the use of immune effector cell-based therapies in hematological and solid cancers, Dr Foy and her team focus on the development and translation of Bristol Myers Squibb’s early IO and cell therapy pipeline from discovery through human proof of concept. As part of her research, Dr Foy also oversees close collaborations with other key research areas across the company, as well as external scientific partnerships. 

Prior to her role at Bristol Myers Squibb, Dr Foy worked at Celgene for more than five years. She was instrumental in establishing Celgene’s Seattle site, focusing initially on building the IO strategy and pipeline, and subsequently expanding focus to include oversight of Celgene’s cell therapy research and early development strategy and pipeline. She and her team spearheaded foundational research in numerous novel targets, including innate immune cells, myeloid cells and regulatory T cells.

Earlier in her career, Dr Foy held Seattle-based scientific leadership positions at Corixa Corp. and GlaxoSmithKline. She also served as the chief scientific officer at VLST, a private company focused on developing therapeutics for autoimmune and inflammatory diseases.

Dr Foy earned her doctorate in immunology from the University of Iowa, a master’s degree in microbiology, and completed her post-doctoral fellowship in immunology at Dartmouth Medical School. Dr Foy has an extensive publication record and holds nearly a dozen patents for novel immune compositions.

Arjun Goyal, MD, MPhil, MBA, is a former Co-Founder and Managing Director of Vida Ventures, a life sciences investment firm that he co-founded in 2017. Dr Goyal previously served as a director on the boards of Scorpion Therapeutics (acquired by Eli Lilly, Inc), Quanta Therapeutics, Inc., Affini-T Therapeutics, Inc., and Alterome Therapeutics, Inc. and he has also led investments roles in Homology Medicines (Nasdaq:FIXX), Pionyr Immunotherapeutics (acquired by Gilead Sciences, Inc.), Peloton Therapeutics (acquired by Merck & Co.) and Asklepios Bio (acquired by Bayer AG). Before Vida Ventures, Dr Goyal was a principal at 5AM Ventures from 2014 to 2017. Dr Goyal received his BS in Medical Science, Diploma in French and his MD degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his MPhil in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Dr Goyal has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He serves on the Committee for the American Australian Association Education Fellowship and is on the Board of Advisors of the MS/MBA Life Sciences Program at Harvard Business School where also serves as a Venture Capital Advisor.

Ramy Ibrahim, MD has more than two decades of drug development experience working in academia, major pharma companies, midsize, startups, and nonprofit organizations. He worked across different therapeutic areas and has expertise with a wide scope of modalities, including immuno-oncology, targeted therapies, and iPSCs. He led teams working both on advancing early-stage therapies (first-in-man studies) and global teams in charge of designing and executing registrational studies.

Prior to becoming Chief Medical and Strategy Officer of Georgiamune in October 2023, he was their senior clinical advisor. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb (BMS) and MedImmune/AstraZeneca, including the global approval of the first checkpoint inhibitor (Yervoy) and advancing the use of immunotherapy into the early stages of disease.

At BMS, Dr Ibrahim was an integral member of the team that developed and ultimately achieved the regulatory approval of the first checkpoint inhibitor that paved the way for immuno-oncology to become the fourth pillar of cancer therapy. He contributed to the early development of PD1 (nivolumab), 41BB, and OX40. He contributed to growing the IO portfolio at MedImmune/AstraZeneca and built the clinical team that ran multiple global registrational studies with IO therapies both as single agents and in combinations.

In 2016, Dr Ibrahim joined the Parker Institute for Cancer Immunotherapy as their founding CMO, where he built a translational, regulatory, and clinical development team that worked with leading immuno-oncology scientists to develop products, INDs, and company creation based on IP generated by Parker investigators, innovators, and scientists. In 2020, he was named a director to the Board of the institute, where he continues to support the ongoing efforts and initiatives. In 2020, he joined bit.bio, a synthetic biology, clinical-stage company that's pioneering iPSCs reprogramming as their first CMO and US president. He played a key role in the fundraising efforts and setting the clinical strategy for their lead programs across different therapeutic areas.

Dr Ibrahim served as a director/board member of cell and gene therapy organizations, including bluebird bio, 2Seventy bio, and the Parker Institute for Cancer Immunotherapy.

Adrelia Allen, PharmD, is a 22-year veteran of the pharmaceutical industry working in sales and clinical research at Merck. She has held positions of increasing experience as a Clinical Research Associate, Clinical Trial Project Manager, and Clinical Research Manager (CRM). She is currently the Executive Director of Clinical Trial Patient Diversity, where she is responsible for the strategy and execution of activities for the diverse representation of patients in clinical trials. Dr Allen has a Doctor of Pharmacy degree from Florida A&M University College of Pharmacy.

Andrew Baum, MD is a former surgeon who has leveraged his deep clinical and scientific expertise to become a visionary leader in the financial services industry and biopharmaceutical sector. He has more than 30 years of experience and a proven track record in leading high-impact research projects and teams, developing robust strategies, and forging global partnerships that have expanded markets and increased investor returns. He is skilled in Equity Research, Hedge Funds, Investment Banking, Strategy, and Equities.

Dr Baum joins Pfizer as Chief Strategy and Innovation Officer, Executive Vice President. He joins Pfizer from Citi where he was the Global Head of Healthcare Research for Citi Research, where he joined in 2011. Prior to this, he covered European Pharmaceuticals at Morgan Stanley for 14 years. He also worked as a UK Pharmaceuticals and Biotechnology analyst at Salomon Brothers. From 1994 to 1996, Dr Baum was a practicing physician at the Royal National Orthopedic Hospital in London and at the John Radcliffe Hospital in Oxford.

Dr Baum has been recognized as the top ranked European Pharmaceutical Analyst six times in the Developed Europe & Emerging EMEA Research Survey, which allows management firms to provide views on the advice they receive from research analysts. His team of analysts consistently ranked in the top three teams in external EU and global investor polls (Institutional Investor, Greenwich, and Reuters).

He has been widely sought after to share his insights with the most senior levels of management within the healthcare industry. He has regularly lectured for a number of prestigious organizations including IO360°, The British Institute of Comparative Law, the World Vaccine Congress as well as occasional presentations to some of the leading management consultancies.

Dr Baum holds an MA degree in Physiological Sciences and a BM ChB degree from Oxford University and is a Fellow of the Royal Society of Medicine.

Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He serves within the Center for Cancer Research (CCR) of the National Cancer Institute as Co-Director of the Center for Immuno-Oncology, the Clinical Director, NCI and the Acting Co-Director of the CCR. He has been an investigator on over 200 trials and has been instrumental in the clinical development of multiple immunotherapeutic agents and has led multiple first-in-human immunotherapy studies through phase 3 clinical trials. He was the coordinating PI of an international study that led to the approval of avelumab for bladder cancer.

Dr. Gulley is the President of SITC . He serves on many national and NIH boards and committees. He has authored over 350 scientific papers or chapters which have been cited over 30,000 times. He has had multiple awards including the 2010 Presidential Early Career Award for Scientists and Engineers, the highest award bestowed by the US President on investigators early in their careers. He also was awarded the 2018 Hubert H. Humphrey Award for Service to America. 

Priti Hegde, PhD, joined Foundation Medicine as the Chief Scientific Officer in August 2019. Dr Hegde oversees clinical product development, cancer genomics, and early-stage research, as well as regulatory and quality assurance, to accelerate advancement of the Company’s leading comprehensive genomic profiling portfolio. She is passionate about innovation in cancer research and translating innovations to precision medicine tools to advance care for patients.

Dr Hegde has spent nearly two decades in the biopharmaceutical industry, with a proven track record in drug development, registration, and commercialization of therapeutics with companion diagnostics in cancer immunotherapy.

Prior to joining Foundation Medicine, Dr Hegde spent 12 years at Genentech, a member of Roche Group, where she held roles of increasing responsibility. Most recently, Dr Hegde served as senior director and principal scientist in oncology biomarker development at Genentech, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy. Dr Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union, as well as its forthcoming diagnostic filings.

Before joining Genentech, Dr Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline. Dr Hegde completed her post-doctoral fellow at The Institute for Genomic Research and holds a PhD in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy from Mumbai University, India.

Jeff Bockman, PhD, is the EVP, Head of Oncology Practice at Defined Health, now known as Cello Health BioConsulting, the firm’s largest practice area. He earned his PhD from Berkeley in Molecular Virology, working on prions, and completed a post-doc at The George Washington School of Medicine. His first stint in industry was at a start-up biotech working on oligonucleotide therapeutics for cancer and infectious diseases.

elly Clark is Head of US Partnerships and Global Site Development at Merck. Ms Clark has been working in the biopharmaceutical industry since 1997 and has spent the last 22 years at Merck in clinical trial operations. She joined Merck Canada as a Clinical Research Associate and advanced through her career as Senior CRA, CRA Manager, Clinical Project Manager, Territory Research Manager, and a Regional Clinical Project Manager Lead for North and South America. She joined Merck US clinical trial operations in 2018 as a Clinical Research Director overseeing specific oncology programs until she moved to her current position in 2022. In her current position, Ms Clark is responsible for leading and developing high quality programs to develop research-naïve and less experienced clinical trial sites with a focus on oncology. She is also responsible for building and sustaining partnerships with key sites across the US which involves supporting them to efficiently execute clinical trials with the highest quality. Ms Clark holds a BScN and a MSHS in Clinical Research Administration from The George Washington University.

François Gaudet, PhD, is the Chief Scientific Officer at Mnemo. Previously, as Director & Head of Multiple Myeloma Drug Discovery at Johnson & Johnson he was the Discovery lead for J&J’s CD3 redirection platform. His team produced five CD3 bispecific antibody programs that entered clinical trials in heme malignancies, including teclistamab (BCMAxCD3) and talquetamab (GPRC5DxCD3), both currently in Phase 2. He was also the Discovery lead for J&J’s internal CAR T platform. Prior to J&J, Dr Gaudet led cancer epigenetics programs at Novartis. Between J&J and Novartis, Dr Gaudet brings nearly 20 years of industry leadership experience in oncology drug discovery. He also authored several scientific publications, including 2 back-to-back papers in Science Magazine. Dr Gaudet did his graduate work at MIT in the lab of Rudolf Jaenisch and received his PhD from the Ludwig Maximilian University of Munich.